Scholars Central

ArticlePublished 2 May 2024

Mechanism of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome along with Therapeutic Strategy

Authors: Kazumi Fujioka

Journal of Bioequivalence & Bioavailability

Volume 16 · Issue 3 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Oxaliplatin is a backbone drug of many regimens for colorectal cancer and colorectal liver metastasis. Most frequent adverse effects in patients with oxaliplatin-based chemotherapy include the peripheral neuropathy, liver dysfunction, splenomegaly, and thrombocytopenia. Recently, the author described a thorough review of the literature on oxaliplatin-induced hepatic complications focusing on Sinusoidal Obstruction Syndrome (SOS), Nodular Regenerative Hyperplasia (NRH), and Focal Nodular Hyperplasia (FNH) in patients with colorectal cancer and colorectal liver metastasis and emphasized the Liver Stiffness Measurement (LSM), elasticity as a novel predictor reflecting splenomegaly by elastography. The underlying mechanisms of oxaliplatin-induced SOS include the activation of inflammation-related pathways, the activated cellular hypoxia, the upregulation of genes involved in coagulation such as Plasminogen Activator Inhibitor-1 (PAI-1) and Von Willebrand Factor (VWF), and the upregulation of angiogenesis-related genes. In this article, current knowledge and trends of the underlying mechanism of oxaliplatin-induced SOS have been reviewed. Additionally, the potential therapies for oxaliplatinbased chemotherapy have been also described. The underlying mechanisms of oxaliplatin-induced SOS showed liver fibrosis, platelet aggregation and adhesion, inflammatory damage, and oxidative stress. The evidence provided that oxidative stress plays a significant role in the pathogenesis of oxaliplatin-induced acute liver injury. Regarding the therapeutic strategy for oxaliplatin-induced SOS, bevacizumab, Vascular Endothelial Growth Factor (VEGF) inhibitor may contribute to the protection of the development of oxaliplatin-induced SOS. Based on the evidence, Glutathione (GSH) might be a potential treatment for oxaliplatin-induced SOS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Kazumi Fujioka”